| June 2020 | CBP501 Phase 1b data published at ASCO |
August 2018 | Granted CBS9106 global license to Stemline Therapeutics, Inc. |
April 2017 | Initiated CBP501 Phase 1b clinical study(dose finding cohort) with CDDP and nivolumab combination in the US. |
June 2016 | IDO/TDO Joint Research Agreement with University of Shizuoka |
April 2016 | Joint Research (screening) Agreement with Fuji Pharma Valley Project. |
March 2016 | Stemline initiated CBS9106 (SL-801) Phase 1 study for solid tumors. |
February 2016 | Joint Research (Drug Efficacy) Agreement with The University of Tokyo Hospital, utilizing their proprietary pancreatic cancer model mouse. |
December 2014 | Granted CBS9106 license (except for Japan, China, Taiwan and South Korea) to Stemline. |
April 2013 | Published preliminary data from CBP501 Phase 2 clinical study in patients with Non Small Cell Lung Cancer(“NSCLC”). |
| June 2012 | CBP501 achieve the primary endpoint of the Phase 2 clinical study in patients with Malignant Pleural Mesothelioma(“MPM”) |
January 2012 | CBP501 received orphan drug designation from FDA for MPM. |
June 2010 | Terminated CBP501 Joint Development Agreement with Takeda Pharmaceutical Co., Ltd. |
September 2009 | Went public on the Tokyo Stock Exchange Mothers Market. |
November 2008 | Initiated CBP501 Phase 2 clinical study in patients with MPM in three drug combinations with Cisplatin and Pemetrexed in the US. |
May 2008 | Initiated CBP501 Phase 1 clinical study in three drug combinations with Cisplatin and Pemetrexed in the US. |
March 2007 | Entered into CBP501 Joint Development Agreement with Takeda. |
| October 2006 | Initiated CBP501 Phase 1 clinical study in two drug combinations with Cisplatin in the US. |
May 2005 | Initiated CBP501 single-drug Phase 1 clinical study in the US. |
January 2001 | Set up the Laboratory in Numazu, Shizuoka. |
2000 | Established CanBas Co., Ltd. in Toyota, Aichi. |